mantle cell lymphoma

From the Field

Real-World Characteristics and Outcomes of Patients With Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Treated With First-Line Bendamustine + Rituximab

04/20/2022

Rouslan Kotchetkov, MD, PhD

David Susman

Erica DiMaria, MD

Lauren Gerard, MD

Derek Nay, MD

Dr Kotchetkov and colleagues assessed the pattern of B-R administration, efficacy and safety in adult patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma with advanced disease and co-morbidities in the real-world setting.

Dr Kotchetkov and colleagues...

04/20/2022

Journal of Clinical Pathways

News

Cost-Effectiveness of KTE-X19 vs Standard of Care for Relapsed/Refractory MCL

03/16/2021

Journal of Clinical Pathways

News

Real-World Practice Patterns, Comorbidities in Medicare Patients With MCL

01/21/2021

Journal of Clinical Pathways

Conference Coverage

Cost-Effectiveness Comparison of BTK Inhibitors for MCL

12/09/2020

Journal of Clinical Pathways

News

Optimal Real-World Immunochemotherapy Regimen for Patients With MCL

06/25/2020

A study presented at the European Hematology Association (EHA) Annual Meeting (June 11-21, 2020) shed light on real-world outcomes in patients with mantle cell lymphoma (MCL) who were treated with rituximab plus...

A...

06/25/2020

Journal of Clinical Pathways

News

Predicting Clinical Outcomes of Patients With High-Risk MCL

06/18/2020

Patients with high-risk mantle cell lymphoma (MCL) biology—defined by blastoid variance, Ki-67 greater than 30%, or high p53 immunohistochemistry expression—are more likely to experience shorter failure-free and...

...

06/18/2020

Journal of Clinical Pathways

News

Modified MIPI Scoring System Provides Clinical, Biological Prognostic Indicators for MCL

06/11/2020

At the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020), researchers from the North American Mantle Cell Lymphoma (MCL) Consortium offered clinical, biological, and genomic markers that...

At the...

06/11/2020

Journal of Clinical Pathways

News

Practice Patterns, Predictors of Survival for Older Patients With MCL

05/27/2020

A new study assessed clinical outcomes and predictors of survival in older patients with mantle cell lymphoma (MCL) treated in the rituximab era. Results of the study are to be presented at the American Society of...

A new...

05/27/2020

Journal of Clinical Pathways

News

Real-World HRU, Costs in Patients With MCL Treated With Drug Combo vs Chemoimmunotherapy

05/20/2020

Researchers recently compared health care resource utilization (HRU) and costs of relapsed or refractory (R/R) mantle cell lymphoma (MCL) patients treated with ibrutinib ± rituximab (I±R) or chemoimmunotherapy (CIT)...

...

05/20/2020

Journal of Clinical Pathways

Research in Review

Patients With MCL and a Specific Mutation in Need of Alternative Frontline Therapies

08/21/2017

JCP Editors

Patients with mantle cell lymphoma (MCL) should be stratified based on the status of a specific mutation and considered for alternative first-line therapy, according to a new study published in Blood (online August...

...

08/21/2017

Journal of Clinical Pathways